

Claims

1. Compound chosen from the following compounds:

- butyl 2-[4-(4-aminophenyl)-1*H*-imidazol-2-yl]ethylcarbamate;
- *N*,2-dimethyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
- 5 - *N*,2-dimethyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
- *N*,3-dimethyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]butan-1-amine;
- *N*,3-dimethyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]butan-1-amine;
- 2,6-di-*tert*-butyl-4-{2-[3-methyl-1-(methylamino)butyl]-1,3-thiazol-4-yl}phenol;
- [4-(3,5-di-*tert*-butylphenyl)-1,3-thiazol-2-yl]methylamine;
- 10 - 2,6-di-*tert*-butyl-4-{2-[(*IS*)-1-(methylamino)ethyl]-1,3-thiazol-4-yl}phenol;
- 2,6-di-*tert*-butyl-4-{2-[(*IR*)-1-(methylamino)ethyl]-1,3-thiazol-4-yl}phenol;
- *N*-{[4-(3,5-di-*tert*-butylphenyl)-1,3-thiazol-2-yl]methyl}-*N*-methylamine;
- *N*-methyl-*N*-{[4-(3,4,5-trimethoxyphenyl)-1,3-thiazol-2-yl]methyl}amine;
- ethyl *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycinate;
- 15 - *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycine;
- 2,6-di-*tert*-butyl-4-{2-[(4-methoxypiperidin-1-yl)methyl]-1,3-thiazol-4-yl}phenol;
- *N*-methyl-*N*-{[(*IS*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
- *N*,2-dimethyl-1-[4-(10-methyl-10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-
- 20 1-amine;
- *N*-methyl-*N*-{[(*IS*)-2-methyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
- 4-{2-[(*IR*)-1-aminoethyl]-1,3-thiazol-4-yl}-2,6-di-*tert*-butylphenol;
- 4-{2-[(*IS*)-1-aminoethyl]-1,3-thiazol-4-yl}-2,6-di-*tert*-butylphenol;
- 25 - 4-[2-(1-aminocyclopropyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol;
- 4-{2-[(methylamino)methyl]-1,3-thiazol-4-yl}benzene-1,2-diol;

- *N*-methyl-*N*-{(1*R*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
 - (1*R*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
 - *N*-methyl-*N*-{(1*R*)-2-methyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
 - 5 - *N*²-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycinamide;
 - ethyl *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}-*N*-(2-ethoxy-2-oxoethyl)glycinate;
 - 4-(3,5-di-*tert*-butyl-4-methoxyphenyl)-2-(methoxymethyl)-1,3-thiazole;
 - 10 - 4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol;
- or a salt of one of the latter.

2. A compound or salt according to claim 1, characterized in that it is butyl 2-[4-(4-aminophenyl)-1*H*-imidazol-2-yl]ethylcarbamate or one of its salts.

3. A compound or salt according to claim 1, characterized in that it is 4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol or one of its salts.

4. As a medicament, a compound chosen from the following compounds:

- butyl 2-[4-(4-aminophenyl)-1*H*-imidazol-2-yl]ethylcarbamate;
- *N*,2-dimethyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
- *N*,2-dimethyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
- 20 - *N*,3-dimethyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]butan-1-amine;
- *N*,3-dimethyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]butan-1-amine;
- 2,6-di-*tert*-butyl-4-{2-[3-methyl-1-(methylamino)butyl]-1,3-thiazol-4-yl}phenol;
- [4-(3,5-di-*tert*-butylphenyl)-1,3-thiazol-2-yl]methylamine;
- 2,6-di-*tert*-butyl-4-{2-[(1*S*)-1-(methylamino)ethyl]-1,3-thiazol-4-yl}phenol;
- 25 - 2,6-di-*tert*-butyl-4-{2-[(1*R*)-1-(methylamino)ethyl]-1,3-thiazol-4-yl}phenol;
- *N*-{[4-(3,5-di-*tert*-butylphenyl)-1,3-thiazol-2-yl]methyl}-*N*-methylamine;
- *N*-methyl-*N*-{[4-(3,4,5-trimethoxyphenyl)-1,3-thiazol-2-yl]methyl}amine;
- ethyl *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycinate;
- *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycine;

- 2,6-di-*tert*-butyl-4-{2-[(4-methoxypiperidin-1-yl)methyl]-1,3-thiazol-4-yl}phenol;
 - *N*-methyl-*N*-{(1*S*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
 - *N*,2-dimethyl-1-[4-(10-methyl-10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
 - 5 - *N*-methyl-*N*-{(1*S*)-2-methyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
 - 4-{2-[(1*R*)-1-aminoethyl]-1,3-thiazol-4-yl}-2,6-di-*tert*-butylphenol;
 - 4-{2-[(1*S*)-1-aminoethyl]-1,3-thiazol-4-yl}-2,6-di-*tert*-butylphenol;
 - 10 - 4-[2-(1-aminocyclopropyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol;
 - 4-{2-[(methylamino)methyl]-1,3-thiazol-4-yl}benzene-1,2-diol;
 - *N*-methyl-*N*-{(1*R*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
 - (1*R*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
 - 15 - *N*-methyl-*N*-{(1*R*)-2-methyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
 - *N*²-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycinamide;
 - ethyl *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}-*N*-(2-ethoxy-2-oxoethyl)glycinate;
 - 20 - 4-(3,5-di-*tert*-butyl-4-methoxyphenyl)-2-(methoxymethyl)-1,3-thiazole;
 - 4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol;
- or a pharmaceutically acceptable salt of one of the latter.

5. Pharmaceutical composition containing, as active ingredient, at least one of the compounds or pharmaceutically acceptable salts mentioned in claim 4.

- 25 **6.** Use of one of the compounds or pharmaceutically acceptable salts mentioned in claim 4 for preparing a medicament intended to treat disorders / pathologies chosen from neurodegenerative diseases, pain and epilepsy.

7. Use according to claim 6, characterized in that the medicament prepared is intended to treat neurodegenerative diseases.

8. Use according to claim 7, characterized in that the compound or pharmaceutically acceptable salt used is chosen from 4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol and pharmaceutically acceptable salts thereof.

5 9. Use according to claim 6, characterized in that the medicament prepared is intended to treat pain.

10. Use according to claim 9, characterized in that the compound or pharmaceutically acceptable salt used is chosen from butyl 2-[4-(4-aminophenyl)-1*H*-imidazol-2-yl]ethylcarbamate and pharmaceutically acceptable salts thereof.